Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) (Q33557634)

28 July 2017

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) (English)

1 reference

28 July 2017

0 references

0 references

1 reference

Harald Matthes

1

1 reference

28 July 2017

Thomas Krummenerl

2

1 reference

28 July 2017

Manfred Giensch

3

1 reference

28 July 2017

Corinna Wolff

4

1 reference

28 July 2017

Jürgen Schulze

5

1 reference

28 July 2017

15 April 2010

1 reference

BMC Complementary and Alternative Medicine

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

13

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

start time

15 April 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1472-6882-10-13

0 references

cites work

Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Prebiotics, synbiotics and inflammatory bowel disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Probiotics and remission of ulcerative colitis: a systematic review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Probiotics in the management of colonic disorders

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

What is the origin of ulcerative colitis? Still more questions than answers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Probiotics: do they help to control intestinal inflammation?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Ulcerative colitis: diagnosis and management

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

A pilot trial of Saccharomyces boulardii in ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Biopsy studies in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Enema therapy for ulcerative colitis patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861635

Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6882-10-13

Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

21 January 2018

1 reference

12 December 2020

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

12 December 2020

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

12 December 2020

[Mutaflor and its medical significance.]

1 reference

12 December 2020

Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?

1 reference

12 December 2020

[Probiotics in chronic inflammatory bowel disease]

1 reference

12 December 2020

Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6882-10-13

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference